(dobutamine) dosing, indications, interactions, adverse effects, and more , , , (dobutamine) dosing, indications, interactions, adverse effects, and more, , , , , , , , , , , , , , , , , Edition:EnglishFrançaisDeutsch, Search, , No Results, News & Perspective, Drugs & Diseases, CME & Education, Log In, Register, , , , , https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cDovL3JlZmVyZW5jZS5tZWRzY2FwZS5jb20vZHJ1Zy9kb2J1dGFtaW5lLTM0MjQzNA==, , , processing.... , , , , , dobutamine (Rx)Brand and Other Names:, Classes: Inotropic Agents, , Dosing & Uses, Interactions, Adverse Effects, Warnings, Pregnancy, Pharmacology, Administration, Images, Patient Handout, Formulary, Dosing & Uses, AdultPediatric, Dosage Forms & Strengths, , infusion solution, in D5W, , 100mg/100mL, , 200mg/100mL, , 400mg/100mL, , , injectable solution, , 12.5mg/mL, , , more... Cardiac Decompensation, , 0.5-1 mcg/kg/min IV continuous infusion initially, then 2-20 mcg/kg/min; not to exceed 40 mcg/kg/min , , Low Cardiac Output (Off-label), , 2-20 mcg/kg/min IV or IO; titrate to desired effect; not to exceed 40 mcg/kg/min, , Dosage Forms & Strengths, , infusion solution, in D5W, , 100mg/100mL, , 200mg/100mL, , 400mg/100mL, , , injectable solution, , 12.5mg/mL, , , more... Cardiac Decompensation, , 0.5-1 mcg/kg/min IV continuous infusion initially, then 2-20 mcg/kg/min; not to exceed 40 mcg/kg/min , , Interactions, Interaction Checker, dobutamine and , No Results, No Interactions Found, Interactions Found, Contraindicated, Serious - Use Alternative, Significant - Monitor Closely, Minor, Sort by : , , Adverse Effects, , 1-10%, , Tachyarrhythmia (~10%), , Hypertension (7.5%), , Eosinophilic myocarditis (≤7%), , Premature ventricular beats (5%; dose related), , Angina (1-3%), , Dyspnea (1-3%) , , Fever (1-3%), , Headache (1-3%), , Nausea (1-3%), , Palpation (1-3%), , , Frequency Not Defined, , Cardiac dysrhythmia, , Exacerbation of coronary arteriosclerosis, , Hypokalemia, , Injection-site reactions, , Syncope, , , Warnings, , Contraindications, , Hypersensitivity, , Idiopathic hypertrophic subaortic stenosis, , , Cautions, , To optimize hemodynamics, correct hypovolemia if needed, , Myocardial infarction (MI), , Severe coronary artery disease (CAD), , Hypertension common; hypotension may also occur, , Increase in ventricular response possible in patients with atrial fibrillation, , Ventricular ectopy exacerbation may occur, , , Pregnancy & Lactation, , Pregnancy category: B, , Lactation: Unknown whether drug is excreted into breast milk; avoid use, , Pregnancy Categories, A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk. B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA:Information not available. more... Pharmacology, , Mechanism of Action, , Strong beta1 and weak beta2/alpha effects, resulting in increased cardiac output, blood pressure, and heart rate, as well as decreased peripheral vascular resistance, , , Absorption, , Onset: 1-10 min , , Duration: 10 min , , Time to peak effect: ~15 min , , , Distribution, , Vd: 0.2 L/kg , , , Metabolism, , Metabolized in tissues and liver by catechol-O-methyl transferase , , Metabolites: Glucuronide conjugate, 3-0-methylated dobutamine (inactive) , , , Elimination, , Half-life: 2 min, , Clearance: 90 mL/kg/min, , Excretion: Urine, , , Administration, , IV Incompatibilities, , Solution: Sodium bicarbonate 5%, , Additive: Acyclovir, alteplase, aminophylline, bretylium(?), bumetanide, calcium chloride(?), calcium gluconate, diazepam, digoxin, floxacillin, furosemide, heparin(?), insulin, magnesium sulfate, phenytoin, potassium phosphates, sodium bicarbonate, , Syringe: Doxapram, , Y-site: Acyclovir, alatrofloxacin, alteplase, aminophylline, amphotericin B cholesteryl sulfate, cefepime, foscarnet, furosemide(?), heparin(?), indomethacin, phytonadione, piperacillin-tazobactam, thiopental, warfarin, , , IV Compatibilities, , Solution: Most common solvents (D5/LR, D5/NS, D5W, LR, NS), , Additive (partial list): Amiodarone, atropine, ciprofloxacin, dopamine, epinephrine, flumazenil, hydralazine, lidocaine, meperidine, morphine sulfate, nitroglycerin, nitroglycerin with nitroprusside(?), norepinephrine, potassium chloride(?), verapamil (incompatible at higher concentrations), , Syringe: Caffeine citrate, heparin, ranitidine, , Y-site (partial list): Amiodarone, atracurium, calcium gluconate, ciprofloxacin, diazepam, diltiazem, dopamine, epinephrine, fentanyl, inamrinone, labetalol, lidocaine, lorazepam, magnesium sulfate, midazolam(?), morphine sulfate, nitroglycerin, norepinephrine, potassium chloride, propofol, sodium nitroprusside, tacrolimus, vasopressin, verapamil, zidovudine, , , IV Preparation, , Solution: Dilute 250 mg in 250 mL of compatible solution to yield final concentration of 1000 mcg/mL; not to exceed 5000 mcg/mL, , , IV Administration, , Infuse into large vein via infusion pump , , , Storage, , Store intact vials at room temperature; protect from excessive heat or freezing conditions, , Diluted solutions may be stored for 24 hours, , , Images, , Patient Handout, Print w/ Office Info, Print w/out Office Info, , Formulary, FormularyPatient Discounts, To view formulary information first create a list of plans. Your list will be saved and can be edited at any time. Create Your List of Plans, Adding plans allows you to:, View the formulary and any restrictions for each plan. Manage and view all your plans together – even plans in different states. Compare formulary status to other drugs in the same class. Access your plan list on any device – mobile or desktop. The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. View explanations for tiers and restrictions, Tier, Description, 1, This drug is available at the lowest co-pay. Most commonly, these are generic drugs. 2, This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs. 3, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs. 4, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. 5, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. 6, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. NC, NOT COVERED, – Drugs that are not covered by the plan. Code, Definition, PA, Prior Authorization, Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription. , QL, Quantity Limits, Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered. , ST, Step Therapy, Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription. , OR, Other Restrictions, Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription. , Done, Add or Remove Plans, Plans for , Select State: , Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, , Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, Non-Medicare PlansMedicare Plans, Select a box to add or remove a plan. close, Select a class to view formulary status for similar drugs, CLOSE, Additional Offers, CLOSE, Email to Patient, From:, To:, The recipient will receive more details and instructions to access this offer. By clicking send, you acknowledge that you have permission to email the recipient with this information. Send, CLOSE, Email Forms to Patient, From:,